Correlative observational study of phase 1 study of RK-163 pulsed human autologous CD14-positive cells (RK-CD14MO) for patients with advanced or relapsed solid tumor

Correlative observational study of phase 1 study of RK-163 pulsed human autologous CD14-positive cells (RK-CD14MO) for patients with advanced or relapsed solid tumor - Correlative observational study of RK-NKT study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032306

Enrollment

Registered

2018-04-19

Start date

2018-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or relapsed solid tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the criteria below are eligible to participate in the study. 1) Patients who have received at least one dose of RK-CD14MO on RK-NKT study (KCTR-D011 study) 2) Patients who do not have anemia (as defined by Hb<9.0g/dL) at the time of enrollment 3) Patients who can give written informed consent to participate in the study

Exclusion criteria

Exclusion criteria: Any patient that the PI/sub-PI deems ineligible to enroll in the study will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
Progression-Free Survival	—

Countries

Japan

Contacts

Public ContactEri Matsuki

Keio University Hospital Clinical and Translational Research Center

eri@keio.jp03-3353-1211

Outcome results